Eli Lilly and Company unveiled sales and earnings expectations for 2021 on 15 December that forecast a year-over-year revenue increase of about 11%, with the company raising its 2020 revenue forecast by $500m. This year’s raised guidance and a portion of next year’s increase were attributed to sales of Lilly’s two COVID-19 treatments – the antibody therapy bamlanivimab and JAK inhibitor Olumiant (baricitinib) – but newer products will provide most of the revenue gains in 2021.
The company also outlined its research and development milestones for next year and announced that it will expand its R&D capabilities by adding a new modality to its portfolio – gene therapy via the purchase of Prevail Therapeutics Inc. Lilly will pay for $22
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?